|
1
|
Grunstein M: Histone acetylation in
chromatin structure and transcription. Nature. 389:349–352. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
ten Holte P, Van Emelen K, Janicot M, Fong
PC, de Bono JS and Arts J: HDAC inhibition in cancer therapy: an
increasingly intriguing tale of chemistry, biology and clinical
benefit. Cancer. Topics in Medicinal Chemistry. Bradbury RH:
Springer Verlag; Berlin: pp. 293–332. 2007
|
|
4
|
Folmer F, Orlikova B, Schneckenburger M,
Dicato M and Diederich M: Naturally occurring regulators of histone
acetylation/deacetylation. Curr Nutr Food Sci. 6:78–99. 2010.
View Article : Google Scholar
|
|
5
|
Seidel C, Schnekenburger M, Dicato M and
Diederich M: Histone deacetylase modulators provided by Mother
Nature. Genes Nutr. Feb 12–2012.(Epub ahead of print).
|
|
6
|
Gibbons RJ: Histone modifying and
chromatin remodelling enzymes in cancer and dysplastic syndromes.
Hum Mol Genet. 14(Suppl 1): R85–R92. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lombardi PM, Cole KE, Dowling DP and
Christianson DW: Structure, mechanism, and inhibition of histone
deacetylases and related metalloenzymes. Curr Opin Struct Biol.
21:735–743. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vannini A, Volpari C, Filocamo G, et al:
Crystal structure of a eukaryotic zinc-dependent histone
deacetylase, human HDAC8, complexed with a hydroxamic acid
inhibitor. Proc Natl Acad Sci USA. 101:15064–15069. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gupta SC, Sundaram C, Reuter S and
Aggarwal BB: Inhibiting NF-kappaB activation by small molecules as
a therapeutic strategy. Biochim Biophys Acta. 1799:775–787. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vallabhapurapu S and Karin M: Regulation
and function of NF-kappaB transcription factors in the immune
system. Annu Rev Immunol. 27:693–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Batra S, Sahu RP, Kandala PK and
Srivastava SK: Benzyl isothiocyanate-mediated inhibition of histone
deacetylase leads to NF-kappaB turnoff in human pancreatic
carcinoma cells. Mol Cancer Ther. 9:1596–1608. 2010. View Article : Google Scholar
|
|
12
|
Jung ID, Lee JS, Jeong YI, et al:
Apicidin, the histone deacetylase inhibitor, suppresses Th1
polarization of murine bone marrow-derived dendritic cells. Int J
Immunopathol Pharmacol. 22:501–515. 2009.PubMed/NCBI
|
|
13
|
Roth SY, Denu JM and Allis CD: Histone
acetyltransferases. Annu Rev Biochem. 70:81–120. 2001. View Article : Google Scholar
|
|
14
|
Kiernan R, Bres V, Ng RW, et al:
Post-activation turn-off of NF-kappa B-dependent transcription is
regulated by acetylation of p65. J Biol Chem. 278:2758–2766. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu J and Colburn NH: Histone deacetylase
inhibition down-regulates cyclin D1 transcription by inhibiting
nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res. 3:100–109.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lehmann A, Denkert C, Budczies J, et al:
High class I HDAC activity and expression are associated with
RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC
Cancer. 9:3952009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Florean C, Schnekenburger M, Grandjenette
C, Dicato M and Diederich M: Epigenomics of leukemia: from
mechanisms to therapeutic applications. Epigenomics. 3:581–609.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schnekenburger M and Diederich M:
Epigenetics offer new horizons for colorectal cancer prevention.
Curr Colorectal Cancer Rep. 8:66–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Papeleu P, Wullaert A, Elaut G, et al:
Inhibition of NF-kappaB activation by the histone deacetylase
inhibitor 4-Me2N-BAVAH induces an early G1 cell cycle arrest in
primary hepatocytes. Cell Prolif. 40:640–655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fabre C, Grosjean J, Tailler M, et al: A
novel effect of DNA methyltransferase and histone deacetylase
inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell
Cycle. 7:2139–2145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Halili MA, Andrews MR, Sweet MJ and
Fairlie DP: Histone deacetylase inhibitors in inflammatory disease.
Curr Top Med Chem. 9:309–319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Srinivasan B, Johnson TE, Lad R and Xing
C: Structure-activity relationship studies of chalcone leading to
3-hydroxy-4,3′,4′,5′-tetramethoxychalcone and its analogues as
potent nuclear factor kappaB inhibitors and their anticancer
activities. J Med Chem. 52:7228–7235. 2009.PubMed/NCBI
|
|
23
|
Yadav VR, Prasad S, Sung B and Aggarwal
BB: The role of chalcones in suppression of NF-kappaB-mediated
inflammation and cancer. Int Immunopharmacol. 11:295–309. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Edwards ML, Stemerick DM and Sunkara PS:
Chalcones: a new class of antimitotic agents. J Med Chem.
33:1948–1954. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lawrence NJ, McGown AT, Ducki S and
Hadfield JA: The interaction of chalcones with tubulin. Anticancer
Drug Des. 15:135–141. 2000.PubMed/NCBI
|
|
26
|
Orlikova B, Tasdemir D, Golais F, Dicato M
and Diederich M: The aromatic ketone 4′-hydroxychalcone inhibits
TNFalpha-induced NF-kappaB activation via proteasome inhibition.
Biochem Pharmacol. 82:620–631. 2011.
|
|
27
|
Pedretti A, Villa L and Vistoli G: VEGA -
an open platform to develop chemo-bio-informatics applications,
using plug-in architecture and script programming. J Comput Aided
Mol Des. 18:167–173. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pedretti A, Villa L and Vistoli G:
Atom-type description language: a universal language to recognize
atom types implemented in the VEGA program. Theor Chem Acc.
109:229–232. 2003. View Article : Google Scholar
|
|
29
|
Tetko IV, Gasteiger J, Todeschini R, et
al: Virtual computational chemistry laboratory - design and
description. J Comput Aided Mol Des. 19:453–463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Friesner RA, Banks JL, Murphy RB, et al:
Glide: a new approach for rapid, accurate docking and scoring. 1.
Method and assessment of docking accuracy. J Med Chem.
47:1739–1749. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Halgren TA, Murphy RB, Friesner RA, et al:
Glide: a new approach for rapid, accurate docking and scoring. 2.
Enrichment factors in database screening. J Med Chem. 47:1750–1759.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ortore G, Di Colo F and Martinelli A:
Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization
of activity trends and selectivities. J Chem Inf Model.
49:2774–2785. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Piccagli L, Fabbri E, Borgatti M, et al:
Docking of molecules identified in bioactive medicinal plants
extracts into the p50 NF-kappaB transcription factor: correlation
with inhibition of NF-kappaB/DNA interactions and inhibitory
effects on IL-8 gene expression. BMC Struct Biol. 8:382008.
View Article : Google Scholar
|
|
34
|
Di Gennaro E, Bruzzese F, Caraglia M,
Abruzzese A and Budillon A: Acetylation of proteins as novel target
for antitumor therapy: review article. Amino Acids. 26:435–441.
2004.PubMed/NCBI
|
|
35
|
Shen KH, Chang JK, Hsu YL and Kuo PL:
Chalcone arrests cell cycle progression and induces apoptosis
through induction of mitochondrial pathway and inhibition of
nuclear factor kappa B signalling in human bladder cancer cells.
Basic Clin Pharmacol Toxicol. 101:254–261. 2007. View Article : Google Scholar
|
|
36
|
Lee ST, Wong PF, Cheah SC and Mustafa MR:
Alpha-tomatine induces apoptosis and inhibits nuclear factor-kappa
B activation on human prostatic adenocarcinoma PC-3 cells. PLoS
One. 6:e189152011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen L, Fischle W, Verdin E and Greene WC:
Duration of nuclear NF-kappaB action regulated by reversible
acetylation. Science. 293:1653–1657. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Krämer OH, Baus D, Knauer SK, et al:
Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev.
20:473–485. 2006.PubMed/NCBI
|
|
39
|
Butler KV, Kalin J, Brochier C, Vistoli G,
Langley B and Kozikowski AP: Rational design and simple chemistry
yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J
Am Chem Soc. 132:10842–10846. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tang W, Luo T, Greenberg EF, Bradner JE
and Schreiber SL: Discovery of histone deacetylase 8 selective
inhibitors. Bioorg Med Chem Lett. 21:2601–2605. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ
and Lee KT: Isoliquiritigenin isolated from the roots of
Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2
expression via the attenuation of NF-kappaB in RAW 264.7
macrophages. Eur J Pharmacol. 584:175–184. 2008.PubMed/NCBI
|
|
42
|
Pandey MK, Sandur SK, Sung B, Sethi G,
Kunnumakkara AB and Aggarwal BB: Butein, a tetrahydroxychalcone,
inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene
expression through direct inhibition of IkappaBalpha kinase beta on
cysteine 179 residue. J Biol Chem. 282:17340–17350. 2007.
View Article : Google Scholar
|
|
43
|
Orlikova B, Tasdemir D, Golais F, Dicato M
and Diederich M: Dietary chalcones with chemopreventive and
chemotherapeutic potential. Genes Nutr. 6:125–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
